Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Completed · Phase 3 · Has a placebo group

Conditions studied: Overactive Bladder

In brief

The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients.

Key facts

Study ID

NCT00311376

Run by

Allergan

People needed

416

Starts

2006-08-01

Expected to finish

2010-05-01

Last updated by the study team

2015-12-04

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord injury or multiple sclerosis
• Inadequate response to anticholinergic medication used to treat overactive bladder

You may not qualify if…

• History of evidence of pelvic or urologic abnormality
• Previous or current diagnosis of bladder or prostate cancer
• Urinary tract infection at time of enrollment

Where it is running

• Study site — Royal Oak, Michigan, United States
• Study site — Randwick, New South Wales, Australia
• Study site — Innsbruck, Austria
• Study site — Ghent, Belgium
• Study site — Sherbrooke, Canada
• Study site — Ostrava, Czechia
• Study site — Garches, France
• Study site — Halle, Germany
• Study site — Christchurch, New Zealand
• Study site — Wroclaw, Poland
• Study site — Moscow, Russia
• Study site — Martin, Slovakia
• Study site — Lviv, Ukraine
• Study site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.